These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Application of natural killer T cells in antitumor immunotherapy. Hong C; Park SH Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797 [TBL] [Abstract][Full Text] [Related]
5. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071 [TBL] [Abstract][Full Text] [Related]
6. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Wu L; Gabriel CL; Parekh VV; Van Kaer L Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798 [TBL] [Abstract][Full Text] [Related]
7. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Venkataswamy MM; Porcelli SA Semin Immunol; 2010 Apr; 22(2):68-78. PubMed ID: 19945296 [TBL] [Abstract][Full Text] [Related]
8. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice. Freigang S; Zadorozhny V; McKinney MK; Krebs P; Herro R; Pawlak J; Kain L; Schrantz N; Masuda K; Liu Y; Savage PB; Bendelac A; Cravatt BF; Teyton L J Clin Invest; 2010 Jun; 120(6):1873-84. PubMed ID: 20484813 [TBL] [Abstract][Full Text] [Related]
9. Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. Venkataswamy MM; Ng TW; Kharkwal SS; Carreño LJ; Johnson AJ; Kunnath-Velayudhan S; Liu Z; Bittman R; Jervis PJ; Cox LR; Besra GS; Wen X; Yuan W; Tsuji M; Li X; Ho DD; Chan J; Lee S; Frothingham R; Haynes BF; Panas MW; Gillard GO; Sixsmith JD; Korioth-Schmitz B; Schmitz JE; Larsen MH; Jacobs WR; Porcelli SA PLoS One; 2014; 9(9):e108383. PubMed ID: 25255287 [TBL] [Abstract][Full Text] [Related]
10. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Padte NN; Li X; Tsuji M; Vasan S Clin Immunol; 2011 Aug; 140(2):142-51. PubMed ID: 21185784 [TBL] [Abstract][Full Text] [Related]
11. Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface. Brennan PJ; Cheng TY; Pellicci DG; Watts GFM; Veerapen N; Young DC; Rossjohn J; Besra GS; Godfrey DI; Brenner MB; Moody DB Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8348-8353. PubMed ID: 28716901 [TBL] [Abstract][Full Text] [Related]
12. [Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation]. Watarai H; Tashiro T; Chiba T; Taniguchi M Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1584-9. PubMed ID: 21089371 [No Abstract] [Full Text] [Related]
13. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Van Kaer L; Parekh VV; Wu L Immunotherapy; 2011 Jan; 3(1):59-75. PubMed ID: 21174558 [TBL] [Abstract][Full Text] [Related]
14. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790 [TBL] [Abstract][Full Text] [Related]
15. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control. Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y Front Immunol; 2018; 9():1266. PubMed ID: 29928278 [TBL] [Abstract][Full Text] [Related]
16. The ins and outs of type I iNKT cell development. Shissler SC; Webb TJ Mol Immunol; 2019 Jan; 105():116-130. PubMed ID: 30502719 [TBL] [Abstract][Full Text] [Related]
17. Activation of invariant natural killer T cells stimulated with microbial α-mannosyl glycolipids. Shimamura M; Yamamura M; Nabeshima T; Kitano N; van den Elzen P; Yesilkaya H; Andrew P; Illarionov P Sci Rep; 2017 Aug; 7(1):9703. PubMed ID: 28852174 [TBL] [Abstract][Full Text] [Related]
18. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers. Singh AK; Rhost S; Löfbom L; Cardell SL Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185 [TBL] [Abstract][Full Text] [Related]
19. Scavenger receptors target glycolipids for natural killer T cell activation. Freigang S; Landais E; Zadorozhny V; Kain L; Yoshida K; Liu Y; Deng S; Palinski W; Savage PB; Bendelac A; Teyton L J Clin Invest; 2012 Nov; 122(11):3943-54. PubMed ID: 23064364 [TBL] [Abstract][Full Text] [Related]